Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36

Abstract

Recently, the retinoblastoma protein interacting zinc finger gene RIZ has been proposed as a candidate for the tumor suppressor locus on 1p36, because of the common loss of RIZ1 RNA in human tumors. In addition, frameshift mutations of this gene have been demonstrated in a variety of tumors with microsatellite instability. Since alterations in this region have been described in malignant melanomas, we investigated DNA of paraffin-embedded sections from 16 typical naevi, 19 atypical naevi, 33 primary melanoma lesions and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis of RIZ. Frameshift mutations in the RIZ gene were found in 17% of melanoma samples and 8.6% of naevi, but we could not demonstrate any missense mutations in the exons of RIZ1. No LOH of the RIZ gene nor any microsatellite instability in six dinucleotide markers or in the mononucleotide repeats IGRIIR, hMSH3, and hMSH6 could be demonstrated in the samples with RIZ frameshift mutations. Although our results do not explain the high rate of deletions in 1p36 found in this tumor, they assign RIZ a potential role in the multi-step tumor forming process of malignant melanoma of the skin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ . 1981 J. Exp. Med. 154: 1764–1778

  • Böni R, Matt D, Voetmeyer A, Burg G, Zhuang Z . 1998 J. Invest. Dermatol. 110: 215–217

  • Catasus L, Matias-Guiu X, Machin P, Zannoni GF, Scambia G, Benedetti-Panici P, Prat J . 2000 Cancer 88: 2290–2297

  • Chadwick RB, Jiang G-L, Bennington GA, Yuan B, Johnson CK, Stevens MW, Niemann TH, Peltomaki P, Huang S, de la Chapelle A . 2000 Proc. Natl. Acad. Sci. USA 97: 2662–2667

  • Dracopoli NC, Harnett P, Bale SJ, Stanger BZ, Tucker MA, Housman DE, Keffort RF . 1989 Proc. Natl. Acad. Sci. USA 86: 4614–4618

  • Fang W, Piao Z, Simon D, Sheu J-C, Huang S . 2000 Genes Chromosomes Cancer 28: 269–275

  • Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, Meltzer SJ . 2000 Cancer Res. 60: 4864–4868

  • He L, Yu JX, Liu L, Buyse IM, Wang MS, Yang QC, Nakagawara A, Brodeur GM, Shi YE, Huang S . 1998 Cancer Res. 58: 4238–4244

  • Heim S, Mitelman F . ed 1995 Cancer Cytogenetics: Chromosomal and molecular genetic aberrations of tumor cells New York: Wiley-Liss

    Google Scholar 

  • Hussein MR, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O . 2001 Am. J. Dermatopathol. 23: 308–314

  • Jiang G-L, Liu L, Buyse IM, Simon D, Huang S . 1999 Int. J. Cancer 83: 541–547

  • Jiang G-L, Huang S . 2000 Histol. Histopathol. 15: 109–117

  • Jiang G-L, Huang S . 2001 Cancer Res. 61: 1796–1798

  • Korabiowska M, Brinck U, Ruschenburg I, Hönig JF, Stachura J, Droese M . 1999 Oncology Rep. 6: 921–923

  • Liu L, Shao G, Steele-Perkins G, Huang S . 1997 J. Biol. Chem. 272: 2984–2991

  • Piao Z, Fang W, Malkhosyan S, Kim H, Horii A, Perucho M, Huang S . 2000 Cancer Res. 60: 4701–4704

  • Poetsch M, Woenckhaus C, Dittberner T, Pambor M, Lorenz G, Herrmann FH . 1998 Lab. Invest. 78: 883–888

  • Poetsch M, Woenckhaus C, Dittberner T, Pambor M, Lorenz G, Herrmann FH . 1999 Virch. Archiv 435: 105–111

  • Poetsch M, Dittberner T, Woenckhaus C . 2001 Cancer Genet. Cytogenet. 125: 21–26

  • Richetta A, Ottini L, Falchetti M, Innocenzi D, Bottoni U, Faiola R, Mariani-Costantini R, Calvieri S . 2001 Melanoma Res. 11: 283–289

  • Sakurada K, Furukawa T, Kato Y, Kayama T, Huang S, Horii A . 2001 Genes Chromosom. Cancer 30: 207–211

  • Siracky J, Blasko M, Borovansky J, Kovarik J, Svec J, Vrba M . 1982 Neoplasma 29: 661–668

  • Talwalkar VR, Scheiner M, Hedges LK, Butler MG, Schwartz HS . 1998 Cancer Genet. Cytogenet. 104: 111–114

  • Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SPL, Emerson S, Trent JM, Nelson MA, Salmon SE, Taetle R . 1995 Cancer Genet. Cytogenet. 83: 93–104

Download references

Acknowledgements

We thank Dr S Burchill for providing the cell lines DX3, MEWO, and LT5.1, and Prof Dr K Schallreuther and Dr N Hibberts for providing the cell line M19. We thank S Seefeldt and M Maschke for excellent technical assistance. The authors would also like to thank two anonymous reviewers for their useful comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Micaela Poetsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poetsch, M., Dittberner, T. & Woenckhaus, C. Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. Oncogene 21, 3038–3042 (2002). https://doi.org/10.1038/sj.onc.1205457

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205457

Keywords

This article is cited by

Search

Quick links